Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HTR2B | P41595 | 3/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888067 | 1.00 | HTR2C (0.48) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL4888076 | 1.00 | HTR2C (0.48) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL4895875 | 0.87 | HTR2C (0.49) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL4892761 | 0.87 | SLC6A2 (0.43) | HTR2CHTR2ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL4895857 | 0.87 | HTR2C (0.49) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL4892758 | 0.87 | SLC6A2 (0.43) | HTR2CHTR2ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL4895859 | 0.87 | HTR2C (0.49) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL4892769 | 0.87 | SLC6A2 (0.43) | HTR2CHTR2ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL4931353 | 0.86 | HTR2C (0.48) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL4931358 | 0.86 | HTR2C (0.48) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | HTR2C 575/4885HTR2A 1682/4885HTR2B 668/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | HTR2C 465/4885HTR2A 1378/4885HTR2B 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.